Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00998738 · ClinicalTrials.gov registry record · Phase 3
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
A Phase 3 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1
- Enrollment target
NCT00998738: Clinical Trial Phase 3 study, sponsored by Mayo Clinic.
NCT00998738 is a Phase 3 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00998738, a Phase 3 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1 participants
- Enrollment target
Study Summary
This randomized phase III trial studies calcium and magnesium to see how well they work in preventing peripheral neuropathy caused by ixabepilone in patients with breast cancer. Giving calcium together with magnesium may stop or delay the development of peripheral neuropathy in patients with cancer who are receiving treatment with ixabepilone. It is not yet known whether calcium and magnesium are effective in preventing peripheral neuropathy caused by ixabepilone.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Placebo
- OTHER Questionnaire Administration
- DRUG Calcium Gluconate
- DRUG Magnesium Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00998738
The ClinicalTrials.gov registry entry for NCT00998738 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT00998738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00998738 about?
NCT00998738 is a clinical study titled "Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer". This randomized phase III trial studies calcium and magnesium to see how well they work in preventing peripheral neuropathy caused by ixabepilone in patients with breast cancer. Giving calcium together with magnesium may stop or delay the development of peripheral neuropathy in patients with cancer ...
What is the current status of trial NCT00998738?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2009-11. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00998738?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Placebo (OTHER), Questionnaire Administration (OTHER), Calcium Gluconate (DRUG), Magnesium Sulfate (DRUG).
Who is sponsoring clinical trial NCT00998738?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.